3 weeks ago
Aurobindo Pharma Q1 profit up 25%, record ₹9,150 crore revenue
A big medicine-making company called Aurobindo Pharma shared how it did in the first three months of its new business year.
The company made more money than it did at the same time last year.
Its profit, which is the money left after paying costs, went up by 25 percent.
The total money the company earned from selling medicines was the highest it has ever made in one three-month period.
That amount was 9,150 crore rupees, which is a very large number.
The growth happened because the company did well in almost all the kinds of business it does.
The company is based in the city of Hyderabad in India.
Its leader, K. Nithyananda Reddy, said they began the new financial year with strong results.
He said their careful work and many different products will help them keep growing in the future.
Aurobindo Pharma's net profit rose 25% to ₹1,032 crore in the quarter ended June 30, 2026.
The company posted record quarterly revenue of ₹9,150 crore, up 16% from ₹7,868 crore a year earlier.
Growth was driven by strength across nearly all of the company's business segments.
Vice-Chairman and Managing Director K. Nithyananda Reddy said the company started FY27 on a strong note.
The results were published on August 5, 2026, with the Hyderabad-based company citing disciplined execution and a diversified product portfolio.
- Who
- Aurobindo Pharma, a Hyderabad-based pharmaceutical company, and its Vice-Chairman and Managing Director K. Nithyananda Reddy.
- What
- Reported a 25% rise in net profit to ₹1,032 crore and record quarterly revenue of ₹9,150 crore.
- Where
- Hyderabad, India.
- When
- First quarter ended June 30, 2026; announced August 5, 2026.
- Why
- Growth was driven by strength across nearly all business segments, disciplined execution, and a diversified product portfolio.
Key facts
- Company
- Aurobindo Pharma
- Headquarters
- Hyderabad
- Quarter
- Q1 FY27 (ended June 30, 2026)
- Net Profit
- ₹1,032 crore (up 25%)
- Previous Year Net Profit
- ₹824 crore
- Revenue
- ₹9,150 crore (record, up 16%)
- Previous Year Revenue
- ₹7,868 crore
- Vice-Chairman & MD
- K. Nithyananda Reddy
Quotes
K. Nithyananda Reddy
Vice‑Chairman and Managing Director of Aurobindo Pharma
“While the global operating environment remains dynamic, our resilient business model, expanding capabilities, and strategic investments position us well to achieve our long‑term growth objectives and create sustained value for our stakeholders.”
thehindubusinessline.com
“We have commenced FY27 on a strong note, delivering healthy growth across our businesses through disciplined execution, operational excellence, and the continued strength of our diversified product portfolio.”
thehindubusinessline.com








